AmericanPharmaceuticalReviewNovember 04, 2021
Tag: BioNet , BIA Separations , vaccines
BioNet, a leading biotech company manufacturing genetically engineered vaccines, and BIA Separations, now part of Sartorius, a leading biochromatography development and manufacturing company, announced the successful development of an optimized mRNA manufacturing process.
BIA’s expertise in chromatographic columns for mRNA purification combined with BioNet’s expertise in the product development of genetic vaccines have, since early 2021, enabled both teams to collaborate on the optimization and upscale of a high-yield mRNA production process.
The new process has been successfully applied to the production of mRNA in the fight against COVID-19. The mRNA vaccine, produced at BioNet’s manufacturing facility, was developed by Chula Vaccine Research Center, Thailand in collaboration with the University of Pennsylvania, US.
Hong Thai Pham, CEO, BioNet commented: “We are very pleased to be collaborating with BIA Separations / Sartorius in developing and tech-transferring optimized mRNA vaccine manufacturing processes. When time is of the essence, it is crucial to be able to rely on key partners whilst maintaining the highest level of quality in every aspect of our work. We are also very proud that our team was able to produce two kinds of genetic vaccines (DNA and mRNA) and we look forward to expanding our partnership with the BIA Separations’ team on future projects.”
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: